Plex Pharmaceuticals

San Diego, United States Founded: 2009 • Age: 17 yrs Acquired By Collidion
Discovering small molecules for diseases caused by protein misfolding such as Parkinsons.
Request Access

About Plex Pharmaceuticals

Plex Pharmaceuticals is a company based in San Diego (United States) founded in 2009 was acquired by Collidion in August 2017.. Plex Pharmaceuticals offers products and services including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors. Plex Pharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.

  • Headquarter San Diego, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Plex Pharmaceuticals, Incorporated
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $298.59 K (USD), Grant

    Jul 01, 2020

  • Investors
    HHS

    & 4 more

  • Employee Count
    Employee Count
  • Acquired by
    Collidion

    (Aug 02, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Plex Pharmaceuticals

Plex Pharmaceuticals offers a comprehensive portfolio of products and services, including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Modulators for heat shock proteins to treat Parkinson's and ALS diseases.

Compounds that enhance alpha-crystallin activity to prevent cataract formation.

Inhibitors of HSP90 and TRAP-1 for treating glioblastoma and brain tumors.

People of Plex Pharmaceuticals
Headcount 1-10
Employee Profiles 3
Board Members and Advisors 1
Employee Profiles
People
Hoji Alimi
Chairman & CEO
People
William H. Watson, III
VP, Business Development
People
Sameer Harish
Director, Finance

Unlock access to complete

Board Members and Advisors
people
Nicholas Dp Cosford
Scientific Advisor

Unlock access to complete

Funding Insights of Plex Pharmaceuticals

  • Total Funding
  • Total Rounds 10
  • Last Round Grant — $298,590
  • First Round

    (05 Apr 2010)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2020 Amount Grant - Plex Pharmaceuticals Valuation

investors

HHS
Feb, 2020 Amount Grant - Plex Pharmaceuticals Valuation

investors

Feb, 2020 Amount Grant - Plex Pharmaceuticals Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Plex Pharmaceuticals

Plex Pharmaceuticals has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include HHS, The Michael J. Fox Foundation and Collidion. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
-
Founded Year Domain Location
Vision research is conducted to eliminate vision loss.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Plex Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Plex Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Plex Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Plex Pharmaceuticals

Plex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Biologics platform developed for intracellular delivery in rare diseases.
domain founded_year HQ Location
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
domain founded_year HQ Location
T-cell-based therapies for autoimmune and degenerative diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Plex Pharmaceuticals

When was Plex Pharmaceuticals founded?

Plex Pharmaceuticals was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is Plex Pharmaceuticals located?

Plex Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

What does Plex Pharmaceuticals do?

Plex Pharmaceuticals (formerly CalAsia Pharmaceuticals), an early stage biotechnology company is focussed on discovering small molecules for diseases caused by protein misfolding such as Amyotrophic lateral sclerosis (ALS), Parkinsons disease. Its technology platform combines functional fragment screening with X-ray crystallography co-crystallization guided by structure-based design approach to design and synthesize New Chemical Entities (NCEs) with drug-like properties. Its discovery programs include modulators of heat shock proteins (Hsp) and FK506 Binding Protein (FKBP) for the treatment of Parkinsons disease (PD) and Amyotrophic lateral sclerosis (ALS); small molecule for the treatment of Glioblastoma multiforme. The company also has discovery and preclinical programs for Zika, Dengue, and West nile virus.

Who are the top competitors of Plex Pharmaceuticals?

Plex Pharmaceuticals's top competitors include Alector, Entrada Therapeutics and Annexon.

What products or services does Plex Pharmaceuticals offer?

Plex Pharmaceuticals offers Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors.

Who are Plex Pharmaceuticals's investors?

Plex Pharmaceuticals has 5 investors. Key investors include HHS, The Michael J. Fox Foundation, Collidion, NIAID, and National Eye Institute.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available